MA26619A1 - Composes azabicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Composes azabicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
MA26619A1
MA26619A1 MA25527A MA25527A MA26619A1 MA 26619 A1 MA26619 A1 MA 26619A1 MA 25527 A MA25527 A MA 25527A MA 25527 A MA25527 A MA 25527A MA 26619 A1 MA26619 A1 MA 26619A1
Authority
MA
Morocco
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
novel substituted
azabicyclic compounds
Prior art date
Application number
MA25527A
Other languages
English (en)
Inventor
Michael Bright Gene
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26619A1 publication Critical patent/MA26619A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Luminescent Compositions (AREA)
MA25527A 1998-04-09 1999-04-07 Composes azabicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant MA26619A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8123798P 1998-04-09 1998-04-09

Publications (1)

Publication Number Publication Date
MA26619A1 true MA26619A1 (fr) 2004-12-20

Family

ID=22162936

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25527A MA26619A1 (fr) 1998-04-09 1999-04-07 Composes azabicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (40)

Country Link
US (2) US6525048B1 (fr)
EP (1) EP1070065B1 (fr)
JP (1) JP3496759B2 (fr)
KR (1) KR100378931B1 (fr)
CN (1) CN1117092C (fr)
AP (1) AP1175A (fr)
AR (1) AR015751A1 (fr)
AT (1) ATE248838T1 (fr)
AU (1) AU749254B2 (fr)
BG (1) BG104915A (fr)
BR (1) BR9909522A (fr)
CA (1) CA2327782A1 (fr)
CO (1) CO5080727A1 (fr)
CZ (1) CZ20003684A3 (fr)
DE (1) DE69910997T2 (fr)
DK (1) DK1070065T3 (fr)
DZ (1) DZ2756A1 (fr)
EA (1) EA003400B1 (fr)
ES (1) ES2204154T3 (fr)
HR (1) HRP20000653A2 (fr)
HU (1) HUP0102400A3 (fr)
ID (1) ID26086A (fr)
IL (1) IL138629A0 (fr)
IS (1) IS5641A (fr)
MA (1) MA26619A1 (fr)
MY (1) MY133390A (fr)
NO (1) NO20005004L (fr)
NZ (1) NZ507010A (fr)
OA (1) OA11496A (fr)
PA (1) PA8469101A1 (fr)
PE (1) PE20000413A1 (fr)
PL (1) PL343408A1 (fr)
PT (1) PT1070065E (fr)
SK (1) SK14782000A3 (fr)
TN (1) TNSN99056A1 (fr)
TR (1) TR200002932T2 (fr)
TW (1) TW555758B (fr)
WO (1) WO1999052907A1 (fr)
YU (1) YU59400A (fr)
ZA (1) ZA992596B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
UA62015C2 (en) 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
PL211402B1 (pl) 1999-09-03 2012-05-31 Apbi Holdings Zastosowanie dapoksetyny do leczenia lub zwalczania przedwczesnej ejakulacji
GB2362826A (en) * 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
WO2003065970A2 (fr) * 2001-02-20 2003-08-14 Royal College Of Surgeons Ie Traitement de la fibromyalgie et du syndrome de fatigue associe au moyen d'antagonistes ou d'agonistes partiels de recepteurs 5ht1a
AP2005003390A0 (en) * 2003-03-12 2005-09-30 Pfizer Prod Inc Pyridyloxymethyl and benzisoxazole azabicyclic derivatives.
WO2005082370A1 (fr) * 2004-01-29 2005-09-09 Pfizer Products Inc. Combinaisons d'un antipsychotique atypique et de derives azabicycliques d'aminomethylpyridyloxy- methyle/benzisoxazole pour le traitement de troubles du systeme nerveux central
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
AR049478A1 (es) 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
AR048112A1 (es) 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
BRPI0512567A (pt) * 2004-06-22 2008-03-25 Pfizer Prod Inc compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas
EP1792629A4 (fr) 2004-08-25 2010-08-25 Takeda Pharmaceutical Agents preventifs/remedes pour l'incontinence de stress et procede de selecetion de ceux-ci
JP2008512441A (ja) * 2004-09-10 2008-04-24 ファイザー・プロダクツ・インク ピリジルオキシメチル、及びベンズイソオキサゾール・アザビシクロ誘導体を使用する、認知障害の治療方法
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
EP3870292A4 (fr) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York Combinaison d'un inhibiteur de réabsorption spécifique de la sérotonine et d'un agoniste partiel du récepteur de la sérotonine 1a pour réduire la dyskinésie induite par l-dopa
WO2020183011A1 (fr) 2019-03-14 2020-09-17 Institut Curie Inhibiteurs de htr1d et leurs utilisations dans le traitement du cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106849A (en) * 1988-05-24 1992-04-21 American Home Products Corporation Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
MX19222A (es) * 1989-01-23 1993-12-01 Pfizer Agentes ansioliticos bis-aza-biciclicos
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
CA2118936A1 (fr) * 1991-09-25 1993-04-01 Gene M. Bright Derives de substitution en 2 de perhydro-1-h-pyrido[1,2-a]pyrazines, agent neuroleptiques
US5262428A (en) * 1992-03-13 1993-11-16 Wake Forest University Biologically active tropane derivatives
ATE185565T1 (de) * 1992-06-16 1999-10-15 Pfizer Verfahren und zwischenprodukte zur herstellung von bis-aza-bicyclischen anxiolytica
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
US5731307A (en) * 1994-09-30 1998-03-24 Pfizer, Inc. Neuroleptic 2,7-disubtituted perhydro-1h-pyrido 1, 2-A!pyrazines
US5614523A (en) * 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems

Also Published As

Publication number Publication date
DK1070065T3 (da) 2003-11-24
US20030181458A1 (en) 2003-09-25
PE20000413A1 (es) 2000-05-25
HUP0102400A3 (en) 2002-10-28
US6525048B1 (en) 2003-02-25
US6887905B2 (en) 2005-05-03
EA003400B1 (ru) 2003-04-24
NZ507010A (en) 2003-05-30
KR20010042527A (ko) 2001-05-25
ATE248838T1 (de) 2003-09-15
DE69910997T2 (de) 2004-05-19
CO5080727A1 (es) 2001-09-25
ZA992596B (en) 2000-10-08
BR9909522A (pt) 2000-12-19
MY133390A (en) 2007-11-30
NO20005004D0 (no) 2000-10-04
WO1999052907A1 (fr) 1999-10-21
TW555758B (en) 2003-10-01
AP9901502A0 (en) 1999-06-30
AR015751A1 (es) 2001-05-16
TNSN99056A1 (fr) 2005-11-10
PL343408A1 (en) 2001-08-13
PT1070065E (pt) 2003-12-31
HUP0102400A2 (hu) 2001-11-28
IS5641A (is) 2000-09-26
PA8469101A1 (es) 2000-09-29
TR200002932T2 (tr) 2001-01-22
AU3268799A (en) 1999-11-01
BG104915A (en) 2001-07-31
SK14782000A3 (sk) 2002-06-04
AP1175A (en) 2003-06-04
CZ20003684A3 (cs) 2002-03-13
EP1070065A1 (fr) 2001-01-24
YU59400A (sh) 2003-10-31
DE69910997D1 (de) 2003-10-09
CA2327782A1 (fr) 1999-10-21
IL138629A0 (en) 2001-10-31
NO20005004L (no) 2000-11-27
ES2204154T3 (es) 2004-04-16
OA11496A (en) 2004-05-14
ID26086A (id) 2000-11-23
JP2002511469A (ja) 2002-04-16
HRP20000653A2 (en) 2001-04-30
CN1117092C (zh) 2003-08-06
DZ2756A1 (fr) 2003-09-15
EA200000910A1 (ru) 2001-04-23
EP1070065B1 (fr) 2003-09-03
JP3496759B2 (ja) 2004-02-16
HK1035719A1 (en) 2001-12-07
KR100378931B1 (ko) 2003-04-07
AU749254B2 (en) 2002-06-20
CN1305477A (zh) 2001-07-25

Similar Documents

Publication Publication Date Title
FR2729951B1 (fr) Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
MA26712A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26730A1 (fr) Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26686A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26680A1 (fr) Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26638A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compoositions pharmaceutiques les contenant
MA26622A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26620A1 (fr) Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26438A1 (fr) Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26614A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26675A1 (fr) Derives d'acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26439A1 (fr) Derives d'indazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26415A1 (fr) Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
MA26462A1 (fr) Composes nouveaux a noyau dibenzocycloheptene, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26624A1 (fr) Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2751334B1 (fr) Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26740A1 (fr) Derives de 13-methyl-erythromycine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26611A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26707A1 (fr) Azalides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26417A1 (fr) Azetidines, procede pour leur preparation, et compositions pharmaceutiques les contenant
MA26501A1 (fr) Derives de quinoleine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant